3ALBANESI C, SCARPONI C, SEBASTIANI S, et al. A cytokine-to-chemokine axis between T lymphocytes and keratinocytes can favor Thl cell accumulation in chronic inflammatory skin disease[J].J I.eukoc Biol,2001,70:617-623.
4WINTERFIELD L S, MENTER A, GORDON K, et al. Psoriasis treatment: current and emerging directed therapies[J].Ann Rheum Dis, 2005,64 : 1187 -- 1190.
5MORTARA L, CASTELLANI P, MEAZZA R, et al. CIITA-induced MHC class II expression in mammary adenoearcinoma leads to a Thl polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory [J].Clin Cancer Res, 2006, 12:3435--3443.
6SAVINKO T, LAUERMA A, LEHTIMAKI S, et al. Topical superantigen exposure induces epidermal accumulation of CD8+ T cells, a mixed Thl/Th2-type dermatitis and vigorous production of IgE antibodies in the murine model of atopic dermatitis[J].J Immunol,2005, 175: 8320-8326.
二级参考文献12
1Schonermark M P, Issing P R, Erbrich B K,et al. Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma. Ann Otol Rhinol Laryngol, 1999,108: 245- 252.
2Shibosawa E,Tsutsumi K,Takakuwa T, et al. Stromal expression of matrix metalloprotease-9 in middle ear cholesteatomas. Am J Otol, 2000,21: 621- 624.
3Schmidt M, Grunsfelder P, Hoppe F. Up-regulation of matrix metalloprotease-9 in middle ear cholesteatomacorrelations with growth factor expression in vivo? Eur Arch Otorhinolaryngol, 2001,258 : 472- 476.
4Kleiner D E, Stetler-Stevenson W G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem, 1994,218: 325 - 329.
5Banerjee A R,Jones J L,Birchall J P,et al. Localization of matrix metalloproteinase-1 in cholesteatoma and deep meatal skin. Otol Neurotol, 2001,22 : 579- 581.
6Lehman D A, Wilmoth J G, Prevatt A R, et al. Inhibition of matrix metalloproteinases in gerbil cholesteatoma:preliminary findings. Otolaryngol Head Neck Surg,2002,126: 404 - 408.
7Sudhoff H,Bujia J,Borkowski G,et al. Basement membrane in middle ear cholesteatoma immunohistochemical and ultrastructural observations. Ann Otol Rhinol Laryngol, 1996,105:804-810.
8Huang C C,Jeffrey M, Abramson M. Interleukin 1 causing bone destruction in middle ear cholesteatoma. Otolaryngol Head Neck Surg, 1987,98: 854- 859.
5Lin YS,Lin LC,Lee FP.The prevalence of chronic otitis media and its complication rates in teenagers and adult patients[J].Otolaryngol Head Neck Surg,2009,140(2):165-170.
6Olszewska E,Wagner M,Bernal-Sprekelsen M,et al.Etiopathogenesis of cholesteatoma[J].Eur Arch Otorhinolaryngol,2004,261(1):6-24.
7Vitale RF,Ribeiro F.The role of Tumor Necrosis Factor-Alpha(TNF-α)in bone resorption present in middle ear cholesteatoma[J].Rev Bras Otorrinolaringol,2007,73(1):123-127.
8Nason R,Jung JY,Chole RA.Lipopolysaccharideinduced osteoclastogenesis from mononuclear precursors:a mechanism for osteolysis in chronic otitis[J].J Assoc Res Otolaryngol,2009,10(2):151-160.
9Jeong JH,Park CW,Tae K,et al.Expression of RANKL and OPG in Middle Ear Cholesteatoma Tissue[J].Laryngoscope,2006,116(7):1180-1184.
10Hofhauer LC,Khosla S,Dunstan CR,et al.The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption[J].Bone Miner Res,2000,15(1):2-12.
